Related Experiment Video
Updated: Feb 28, 2026

Author Spotlight: A Multi-Depth Porcine Model for Comprehensive Study of Burn Injuries and Healing Processes
Published on: February 23, 2024
Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds
Johanneke J Akershoek1,2, Katrien M Brouwer1,2, Marcel Vlig2
1Department of Plastic, Reconstructive and Hand Surgery, Research Institute MOVE, VU University Medical Center, Amsterdam, The Netherlands.
Abstract:
Healing of burn wounds is often associated with scar formation due to excessive inflammation and delayed wound closure. To date, no effective treatment is available to prevent the fibrotic process. The Renin Angiotensin System (RAS) was shown to be involved in fibrosis in various organs. Statins (e.g. Atorvastatin), Angiotensin receptor antagonists (e.g. Losartan) and the combination of these drugs are able to reduce the local RAS activation, and reduced fibrosis in other organs. We investigated whether inhibition of the RAS could improve healing of burn wounds by treatment with Atorvastatin, Losartan or the combination of both drugs. Therefore, full and partial thickness burn wounds were inflicted on both flanks of Yorkshire pigs. Oral administration of Atorvastatin, Losartan or the combination was started at post-burn day 1 and continued for 28 days. Full thickness wounds were excised and transplanted with an autologous meshed split-thickness skin graft at post-burn day 14. Partial thickness wounds received conservative treatment. Atorvastatin treatment resulted in enhanced graft take and wound closure of the full thickness wounds, faster resolution of neutrophils compared to all treatments and reduced alpha-smooth muscle actin positive cells compared to control treatment. Treatment with Losartan and to a lesser extent the combination therapy resulted in diminished graft take, increased wound contraction and poorer scar outcome. In contrast, Losartan treatment in partial thickness wounds decreased the alpha-smooth muscle actin+ fibroblasts and contraction. In conclusion, we showed differential effects of Losartan and Atorvastatin in full and partial thickness wounds. The extensive graft loss seen in Losartan treated wounds is most likely responsible for the poor clinical outcome of these full thickness burn wounds. Therefore, Losartan treatment should not be started before transplantation in order to prevent graft loss. Atorvastatin seems to accelerate the healing process in full thickness wounds possibly by dampening the pro-inflammatory response.
Insights
Atorvastatin improved burn wound healing and graft take in pigs by reducing inflammation, while Losartan impaired healing in full-thickness wounds. Differential effects highlight targeted therapeutic potential for burn scar prevention.
Area of Science:
- Regenerative Medicine
- Wound Healing Research
- Dermatology
Background:
- Burn wound healing often involves excessive inflammation and fibrosis, leading to scarring.
- The Renin Angiotensin System (RAS) plays a role in fibrotic processes in various organs.
- Statins and Angiotensin Receptor Blockers (ARBs) can modulate local RAS activity and reduce fibrosis.
Purpose of the Study:
- To investigate the efficacy of Atorvastatin, Losartan, or their combination in improving burn wound healing.
- To assess the impact of RAS inhibition on fibrosis and scar formation in burn wounds.
- To evaluate differential effects on full-thickness and partial-thickness burn models.
Main Methods:
- Yorkshire pigs received full and partial thickness burn wounds.
- Oral administration of Atorvastatin, Losartan, or combination therapy initiated on post-burn day 1 for 28 days.
- Full-thickness wounds underwent split-thickness skin grafting; partial-thickness wounds received conservative care.
Main Results:
- Atorvastatin enhanced graft take and wound closure in full-thickness wounds, with reduced neutrophils and alpha-smooth muscle actin (α-SMA) positive cells.
- Losartan and combination therapy diminished graft take, increased wound contraction, and worsened scar outcomes in full-thickness wounds.
- Losartan reduced α-SMA+ fibroblasts and contraction in partial-thickness wounds, indicating differential effects based on wound type.
Conclusions:
- Atorvastatin accelerates healing in full-thickness burn wounds, potentially by reducing inflammation.
- Losartan negatively impacts graft survival in full-thickness wounds, suggesting delayed administration post-transplantation.
- RAS inhibition demonstrates differential effects on burn wound healing, necessitating tailored therapeutic strategies.
Related Concept Videos
Burn Injuries
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

